ArticleFrontiers in pharmacology2026
Dimethyl malonate suppresses succinate dehydrogenase to alleviate ischemia/reperfusion-induced acute lung injury.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemia/reperfusion (IR) injury is a pivotal contributor to acute lung injury (ALI) for which effective treatment options are currently lacking. Following ischemia, succinate accumulation and reoxidation by succinate dehydrogenase (SDH) during reperfusion induce excessive reactive oxygen species production, causing significant tissue damage. Dimethyl malonate (DMM), a competitive SDH inhibitor, has shown promise in treating various forms of IR-induced damage, but its effects on IR-induced ALI remain unexplored. To our knowledge, this is the first study to demonstrate in an Methods: Isolated rat lungs subjected to ischemia (40 min) followed by reperfusion (60 min) were treated with various DMM concentrations (2 mM, 4 mM, and 8 mM) and 8 mM dimethyl succinate (DMS, a cell-permeable derivative of succinate). At the end of the experiment, bronchoalveolar lavage fluid and lung tissues were collected and analyzed. Target engagement was verified by measuring SDH enzymatic activity. Additionally, mouse lung epithelial (MLE)-12 cells underwent hypoxia-reoxygenation (HR) to investigate the cellular impact of DMM. Results: Metabolomic analysis revealed that succinate accumulated significantly in lung tissue after IR injury. DMM treatment effectively suppressed the IR-induced elevation of SDH enzymatic activity in both lung tissues and MLE-12 cells. Consequently, DMM dose-dependently reduced pulmonary edema and protein levels in bronchoalveolar lavage fluid. DMM also improved lung injury scores and attenuated proinflammatory cytokine production, apoptosis, and oxidative stress. These protective effects were associated with upregulated Nrf2/HO-1 activity and inhibited NF-κB signaling, all of which were reversed by DMS supplementation. Similar results were observed in MLE-12 cells following HR. Conclusion: These findings suggest that inhibiting SDH with DMM has considerable potential for mitigating IR-induced ALI. The therapeutic application of DMM could be a promising approach for alleviating IR-induced ALI severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.